Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANIX |
---|---|---|
09:32 ET | 1788 | 3.03 |
09:45 ET | 724 | 2.96 |
09:48 ET | 400 | 2.995 |
10:10 ET | 1998 | 2.9801 |
10:15 ET | 139 | 2.98 |
10:28 ET | 100 | 2.98 |
10:50 ET | 338 | 2.99 |
10:51 ET | 2150 | 3 |
10:53 ET | 100 | 2.98 |
10:55 ET | 610 | 2.985 |
11:00 ET | 100 | 2.99 |
11:08 ET | 600 | 2.99 |
11:18 ET | 100 | 2.97 |
11:29 ET | 744 | 3 |
11:58 ET | 1400 | 2.98 |
12:09 ET | 110 | 2.9723 |
12:25 ET | 122 | 2.98 |
12:30 ET | 150 | 2.9784 |
12:48 ET | 200 | 2.97 |
01:10 ET | 100 | 2.98 |
01:14 ET | 2592 | 3 |
01:37 ET | 215 | 3.0196 |
01:42 ET | 100 | 3.0072 |
01:57 ET | 200 | 3.005 |
02:08 ET | 100 | 2.99 |
02:09 ET | 100 | 3 |
02:13 ET | 150 | 2.9944 |
02:22 ET | 100 | 3.01 |
02:29 ET | 3300 | 3.0299 |
02:33 ET | 500 | 3.01 |
02:45 ET | 200 | 3 |
02:49 ET | 348 | 3.0086 |
03:05 ET | 1500 | 2.99 |
03:07 ET | 2200 | 2.98 |
03:23 ET | 1300 | 2.97 |
03:30 ET | 1350 | 2.97 |
03:41 ET | 1943 | 2.96 |
03:43 ET | 300 | 2.95 |
03:48 ET | 680 | 2.955 |
03:52 ET | 800 | 2.96 |
03:54 ET | 100 | 2.96 |
03:56 ET | 315 | 2.95 |
03:57 ET | 374 | 2.98 |
03:59 ET | 901 | 2.97 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Anixa Biosciences Inc | 94.7M | -8.6x | --- |
Chimerix Inc | 94.1M | -1.1x | --- |
Genelux Corp | 97.5M | -3.0x | --- |
IO Biotech Inc | 92.9M | -0.7x | --- |
Passage Bio Inc | 91.2M | -0.8x | --- |
Elicio Therapeutics Inc | 98.7M | -1.1x | --- |
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $94.7M |
---|---|
Revenue (TTM) | $210.0K |
Shares Outstanding | 31.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-0.35 |
Book Value | $0.78 |
P/E Ratio | -8.6x |
Price/Sales (TTM) | 451.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,744.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.